专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5563036A Transcription factor-DNA binding assay 失效
标题翻译：转录因子-DNA结合测定
公开(公告)号：US5563036A
公开(公告)日：1996-10-08
申请号：US235503
申请日：1994-04-29
申请人： Michael G. Peterson , Vijay R. Baichwal , Berta Strulovici
发明人： Michael G. Peterson , Vijay R. Baichwal , Berta Strulovici
IPC分类号： G01N33/566 , C12N15/09 , C12Q1/68 , C12Q1/70 , G01N33/50
CPC分类号： G01N33/5008 , C12Q1/6811 , C12Q1/6813 , C12Q1/6876 , C12Q1/701 , C12Q2600/136
摘要： Pharmacological agents useful in the diagnosis or treatment of disease associated with the expression of a gene are identified in high throughput drug screening assays. The methods involve combining a labeled transcription factor, a nucleic acid coupled to a ligand, a candidate pharmacological agent and a receptor immobilized on a solid substrate, such as a microtiter plate, filter, or bead. The nucleic acid has at least that portion of a nucleotide sequence naturally involved in the regulation of the transcription of the gene which is necessary for sequence-specific interaction with the transcription factor. The resultant combination is incubated under conditions whereby the receptor is bound to the ligand and, but for the presence of said candidate pharmacological agent, the transcription factor is sequence-specifically bound to the nucleic acid. Unbound transcription factor is then removed or washed from the solid substrate and labelled, sequence-specifically bound transcription factor is detected. Incubates which include candidate agents which alter transcription factor binding deviate from control incubates in terms of label signal--typically, binding is disrupted and the signal is diminished. In a preferred embodiment, the entire process is performed by a computer-controllable electromechanical robot with an axial rotatable arm.
摘要翻译：用于诊断或治疗与基因表达相关的疾病的药理学试剂在高通量药物筛选试验中鉴定。所述方法包括将标记的转录因子，与配体偶联的核酸，候选药理学试剂和固定在固体基质如微量滴定板，过滤器或珠上的受体组合。该核酸至少具有与转录因子的序列特异性相互作用所必需的天然参与调节基因转录的核苷酸序列的那部分。将所得组合在受体结合于配体的条件下孵育，并且对于所述候选药理学试剂的存在，转录因子与核酸序列特异性结合。然后从固体底物中除去或洗涤未结合的转录因子，并检测到标记的序列特异性结合的转录因子。包括候选药物的孵化物，其通过改变转录因子结合偏离对照培养物的标签信号（通常结合）被破坏并且信号减弱。在优选实施例中，整个过程由具有轴向可旋转臂的计算机可控机电机器人执行。

2. 发明申请

US20160367541A1 THERAPEUTIC AND DIAGNOSTIC METHODS 审中-公开
标题翻译：治疗和诊断方法
公开(公告)号：US20160367541A1
公开(公告)日：2016-12-22
申请号：US14539720
申请日：2014-11-12
申请人： Tracey C. Fleischer , Daniel M. Cimbora , Jeffrey S. Flick , Andrew D. Gassman , Vijay R. Baichwal , Damon I. Papac
发明人： Tracey C. Fleischer , Daniel M. Cimbora , Jeffrey S. Flick , Andrew D. Gassman , Vijay R. Baichwal , Damon I. Papac
IPC分类号： A61K31/455 , A61K31/444 , A61K31/4406 , A61K31/4439 , A61K31/4545 , A61K31/4184 , A61K31/517 , A61K31/496 , A61K31/4436 , A61K31/5377 , A61K31/519 , A61K31/4468 , A61K31/506 , A61K31/4725 , A61K31/45 , C12Q1/68 , G01N33/574 , A61K31/635
CPC分类号： A61K31/455 , A61K31/4184 , A61K31/4406 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4468 , A61K31/45 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/535 , A61K31/5377 , A61K31/635 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57496 , G01N2800/52 , A61K2300/00
摘要： The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
摘要翻译：本发明涉及治疗对抑制烟酰胺磷酸核糖基转移酶（Nampt）有利的疾病，特别是癌症的方法; 它还涉及利用Nampt抑制剂与NAD生物合成前体组合有意杀死癌细胞同时限制或最小化对正常宿主细胞的毒性的治疗方法; 并且其涉及鉴定对Nampt抑制剂治疗最有反应的癌症的方法，特别是当与烟酸组合施用时。

3. 发明授权

US08912184B1 Therapeutic and diagnostic methods 有权
标题翻译：治疗和诊断方法
公开(公告)号：US08912184B1
公开(公告)日：2014-12-16
申请号：US13235221
申请日：2011-09-16
申请人： Tracey C. Fleischer , Daniel M. Cimbora , Jeffrey S. Flick , Andrew D. Gassman , Vijay R. Baichwal , Damon I. Papac
发明人： Tracey C. Fleischer , Daniel M. Cimbora , Jeffrey S. Flick , Andrew D. Gassman , Vijay R. Baichwal , Damon I. Papac
IPC分类号： A61K31/535
CPC分类号： A61K31/455 , A61K31/4184 , A61K31/4406 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4468 , A61K31/45 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/535 , A61K31/5377 , A61K31/635 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57496 , G01N2800/52 , A61K2300/00
摘要： The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
摘要翻译：本发明涉及治疗对抑制烟酰胺磷酸核糖基转移酶（Nampt）有利的疾病，特别是癌症的方法; 它还涉及利用Nampt抑制剂与NAD生物合成前体联合有意杀死癌细胞同时限制或最小化对正常宿主细胞的毒性的治疗方法; 并且其涉及鉴定对Nampt抑制剂治疗最有反应的癌症的方法，特别是当与烟酸组合施用时。

4. 发明申请

US20120277257A1 Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms 审中-公开
标题翻译：治疗疾病，药物组合物和药物剂型的方法
公开(公告)号：US20120277257A1
公开(公告)日：2012-11-01
申请号：US13470914
申请日：2012-05-14
申请人： Margaret YU , Daniel A. WETTSTEIN , Vijay R. BAICHWAL , Damon I. PAPAC , Gaylen M. ZENTNER , Mark S. WILLIAMS
发明人： Margaret YU , Daniel A. WETTSTEIN , Vijay R. BAICHWAL , Damon I. PAPAC , Gaylen M. ZENTNER , Mark S. WILLIAMS
IPC分类号： A61K31/52 , A61P35/00 , B29B9/00 , A61P35/02
CPC分类号： A61K31/4188 , A61K31/445
摘要： Disclosed herein are methods of treating diseases and disorders responsive to inhibition of Hsp90, pharmaceutical compositions, pharmaceutical dosage forms and medicaments useful for the treatment of diseases responsive to inhibition of Hsp90, and methods of making the pharmaceutical compositions, pharmaceutical dosage forms and medicaments.
摘要翻译：本文公开了治疗对Hsp90抑制作用的疾病和病症的方法，药物组合物，药物剂型和可用于治疗对Hsp90抑制作用的疾病的药物，以及制备药物组合物，药物剂型和药物的方法。

5. 发明授权

US06211337B1 RIP: novel human protein involved in tumor necrosis factor signal transduction 失效
标题翻译： RIP：涉及肿瘤坏死因子信号转导的新型人类蛋白质
公开(公告)号：US06211337B1
公开(公告)日：2001-04-03
申请号：US09132118
申请日：1998-08-11
申请人： Vijay R. Baichwal , Jianing Huang , Hailing Hsu , David V. Goeddel
发明人： Vijay R. Baichwal , Jianing Huang , Hailing Hsu , David V. Goeddel
IPC分类号： C07K14435
CPC分类号： C07K14/47 , A61K38/00 , C07K14/7151
摘要： The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
摘要翻译：本发明涉及人受体相互作用蛋白（hRIP），编码hRIP的核酸和使用该主题组合物的方法; 特别是诸如基于hRIP的体外结合测定法和用于筛选用于药理学试剂的铅化合物的化学文库的磷酸化测定的方法。

6. 发明授权

US07029871B2 RIP: a human protein involved in tumor necrosis factor signal transduction 失效
标题翻译： RIP：参与肿瘤坏死因子信号转导的人类蛋白质
公开(公告)号：US07029871B2
公开(公告)日：2006-04-18
申请号：US09758003
申请日：2001-01-09
申请人： Vijay R. Baichwal , Jianing Huang , Hailing Hsu , David V. Goeddel
发明人： Vijay R. Baichwal , Jianing Huang , Hailing Hsu , David V. Goeddel
IPC分类号： C12N15/00 , C12N15/12 , C12N15/63 , C07K14/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/7151
摘要： The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
摘要翻译：本发明涉及人受体相互作用蛋白（hRIP），编码hRIP的核酸和使用该主题组合物的方法; 特别是诸如基于hRIP的体外结合测定法和用于筛选用于药理学试剂的铅化合物的化学文库的磷酸化测定的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式